07:00 Tue 27 Apr 2021
SkinBioTherapeutics - Initiation of oral health development programme
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
SkinBioTherapeutics initiates new oral health development programme
in partnership with the University of Manchester
The oral health programme will explore the use of different bacteria, including SkinBioTherapeutics' proprietary lysate, SkinBiotix®, for oral health and well-being. The programme will be led by Professor
The 12-month programme will develop and test formulations designed to support the health of skin surfaces in the oral cavity targeting disease prevention, oral care and hygiene.
Good oral health is an essential part of general health and well-being. The epithelia, or 'skin', surfaces within the oral cavity are considered gatekeepers that play a critical role in protection. These surfaces operate both as a physical and biological barrier, that react to harmful external stimuli by triggering protective and repair responses. Supporting this skin layer of cells to respond and to remain healthy not only helps support oral health but also plays an important role in oral and systemic disease prevention.
Management believes that focusing on the health of the cells within the oral cavity is a potentially innovative approach to developing a suite of oral healthcare formulations. These formulations could be positioned as standalone products or could work synergistically with traditional oral health and wellbeing products.
The global market for oral care was
"This new oral health programme builds and expands on our work in skin health and applies our already substantial skin microbiome expertise to the global oral care marketplace. This new strand to our development portfolio also presents near term opportunities.
"We believe there is significant potential in oral care for innovative natural products with anti-microbial characteristics that can build long lasting protection against disease. This is an exciting new step for us."
Prof
"Our work on the skin's epithelial barrier, the immune system and the role and importance of the microbiome in health and disease naturally extends into the other important environmental barriers such as those in the oral cavity. It is well understood that the epithelial surfaces in the oral cavity play vital roles in protecting us from disease. By investigating how our technology can be applied to support the health of the oral epithelia, we hope to demonstrate its potential in oral healthcare and disease prevention."
-Ends-
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by
For more information please contact:
SkinBioTherapeutics plc Stuart J. Ashman, CEO |
Tel: +44 (0) 161 468 2760 |
Cenkos Securities Plc (Nominated Adviser & Broker) |
Tel: +44 (0) 20 7397 8900 |
Instinctif Partners |
Tel: +44 (0) 20 7457 2020 |
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Prof.
The Company has demonstrated, through scientific testing, that the SkinBiotix® platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.
The Company listed on AIM in
visit: www.skinbiotix.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE